There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...

Vanda claims that two generics to its sleep disorder drug Hetlioz were approved despite inadequate data and is requesting ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...

Krystal Biotech's decision follows the FDA’s rejection last month of Replimune’s RP1, which works similarly to Krystal ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

While it’s impossible to make apples-to-apples comparisons of the many obesity candidates with so many differences across ...

In Phase III studies, Tonmya showed significantly superior analgesic effects in patients with fibromyalgia versus placebo.

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

The small molecule, vatiquinone, had already flunked a Phase III trial, but the company pushed ahead with an approval bid ...

In an open letter, Health and Human Services employees asked the Secretary to stop and disavow the spread of health ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...